SAFI BIOTHERAPEUTICS AWARDED A $4.7 MILLION EXTENSION BY U.S. DOW TO ADVANCE MANUFACTURED RED BLOOD CELLS TOWARD FIRST CLINICAL TRIAL

Reuters · 1d ago

Please log in to view news